VINCENT Y WANG
Allopathic & Osteopathic Physicians|Internal Medicine FLUSHING, NY NPI 1194737486
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine NY Amgen Inc. All categories
General Payments — all program years on this page
$22,631.56
- Category: General Payments
- Program years: PY2018–2024
- Record count: 744
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $2,912.21 across 94 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,877.61 | 92 |
| Education | $34.60 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $992.53 | 17 |
| ABBVIE INC. | $406.70 | 14 |
| Merck Sharp & Dohme Corporation | $232.10 | 6 |
| PFIZER INC. | $137.17 | 6 |
| IDORSIA PHARMACEUTICALS US INC | $125.00 | 1 |
| INTRA-SANA LABORATORIES | $114.60 | 5 |
| Novo Nordisk AS | $94.95 | 5 |
| IBSA Pharma Inc. | $88.71 | 5 |
| Gilead Sciences, Inc. | $75.48 | 3 |
| Acerta Pharma LLC | $72.81 | 4 |
| Otsuka America Pharmaceutical, Inc. | $68.51 | 3 |
| GlaxoSmithKline, LLC. | $62.02 | 3 |
| Astellas Pharma US Inc | $52.74 | 3 |
| SCPHARMACEUTICALS INC. | $48.78 | 2 |
| Phathom Pharmaceuticals, Inc. | $45.24 | 2 |
| Lilly USA, LLC | $44.02 | 2 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.93 | 2 |
| OPKO Pharmaceuticals, LLC | $34.60 | 2 |
| Ardelyx, Inc. | $24.26 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $23.18 | 1 |
| Esperion Therapeutics, Inc. | $22.73 | 1 |
| IRONWOOD PHARMACEUTICALS, INC | $21.84 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $18.76 | 1 |
| BAXTER HEALTHCARE | $17.98 | 1 |
| CALLIDITAS THERAPEUTICS US INC. | $17.68 | 1 |
| Kowa Pharmaceuticals America, Inc. | $16.61 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $15.28 | 1 |
By program year
Records — PY2024 (94)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.